Renalytix Plc (AIM:RENX)
2.500
+0.300 (13.64%)
Mar 26, 2026, 3:02 PM GMT
Renalytix Revenue
In the fiscal year ending June 30, 2025, Renalytix had annual revenue of $3.00M USD with 30.43% growth. Renalytix had revenue of $522.00K in the quarter ending September 30, 2024, with 13.73% growth.
Revenue
$3.00M
Revenue Growth
+35.07%
P/S Ratio
4.19
Revenue / Employee
$65.22K
Employees
46
Market Cap
10.27M GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 3.00M | 700.00K | 30.43% |
| Jun 30, 2024 | 2.30M | -1.10M | -32.41% |
| Jun 30, 2023 | 3.40M | 433.00K | 14.58% |
| Jun 30, 2022 | 2.97M | 1.48M | 99.20% |
| Jun 30, 2021 | 1.49M | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 43.64B |
| GSK plc | 32.67B |
| Haleon | 11.03B |
| Smith & Nephew | 4.58B |
| RUA Life Sciences | 4.46M |
| GENinCode | 2.91M |
| CelLBxHealth | 2.62M |
| Fusion Antibodies | 1.60M |
Renalytix News
- 4 months ago - Pivotal kidneyintelX.dkd Data Published in Diabetes Care, Considered the Leading Clinical Journal Worldwide in Diabetes - PRNewsWire
- 6 months ago - Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease - PRNewsWire
- 8 months ago - MVP Health Care and Renalytix Partner to Bring Life-Changing Kidney Disease Testing to Local Communities - PRNewsWire
- 1 year ago - Renalytix Plc (RNLXY) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Renalytix plc Reports Financial Results for First Quarter of Fiscal Year 2025 - PRNewsWire